CR20210590A - Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1 - Google Patents

Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1

Info

Publication number
CR20210590A
CR20210590A CR20210590A CR20210590A CR20210590A CR 20210590 A CR20210590 A CR 20210590A CR 20210590 A CR20210590 A CR 20210590A CR 20210590 A CR20210590 A CR 20210590A CR 20210590 A CR20210590 A CR 20210590A
Authority
CR
Costa Rica
Prior art keywords
strong
compound
structural formula
preparation
xpo1 inhibitors
Prior art date
Application number
CR20210590A
Other languages
English (en)
Spanish (es)
Inventor
Brian Clinton Austad
David G Roe
Original Assignee
Karyopharm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karyopharm Therapeutics Inc filed Critical Karyopharm Therapeutics Inc
Publication of CR20210590A publication Critical patent/CR20210590A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CR20210590A 2019-05-01 2020-05-01 Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1 CR20210590A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962841649P 2019-05-01 2019-05-01
PCT/US2020/031124 WO2020223678A1 (en) 2019-05-01 2020-05-01 Process for preparing xpo1 inhibitors and intermediates for use in the preparation of xp01 inhibitors

Publications (1)

Publication Number Publication Date
CR20210590A true CR20210590A (es) 2022-03-11

Family

ID=70802955

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210590A CR20210590A (es) 2019-05-01 2020-05-01 Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1

Country Status (14)

Country Link
US (1) US12479806B2 (cg-RX-API-DMAC7.html)
EP (1) EP3962898A1 (cg-RX-API-DMAC7.html)
JP (2) JP7630444B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004142A (cg-RX-API-DMAC7.html)
CN (1) CN114040909B (cg-RX-API-DMAC7.html)
AU (1) AU2020266170B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021706A2 (cg-RX-API-DMAC7.html)
CA (1) CA3135712A1 (cg-RX-API-DMAC7.html)
CR (1) CR20210590A (cg-RX-API-DMAC7.html)
IL (1) IL287673B1 (cg-RX-API-DMAC7.html)
MA (1) MA55808A (cg-RX-API-DMAC7.html)
MX (1) MX2021013211A (cg-RX-API-DMAC7.html)
SG (1) SG11202111993SA (cg-RX-API-DMAC7.html)
WO (1) WO2020223678A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
JP2021048976A (ja) * 2019-09-24 2021-04-01 株式会社ユニバーサルエンターテインメント 遊技機
CN112679477B (zh) * 2020-12-17 2021-10-26 佛山奕安赛医药科技有限公司 塞利尼索及其中间体的制备方法
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) 2011-07-29 2016-10-12 カリオファーム セラピューティクス,インコーポレイテッド 核内輸送調節因子およびその使用
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3397634A1 (en) 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
WO2017118940A1 (en) * 2016-01-08 2017-07-13 Dr. Reddy's Laboratories Limited Solid forms of selinexor and process for their preparation
EP3565813A1 (en) * 2017-01-05 2019-11-13 Watson Laboratories, Inc. Novel crystalline forms of selinexor and process for their preparation
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法

Also Published As

Publication number Publication date
AU2020266170A1 (en) 2021-11-25
US20220242832A1 (en) 2022-08-04
JP2025072490A (ja) 2025-05-09
JP2022531576A (ja) 2022-07-07
JP7850834B2 (ja) 2026-04-23
CA3135712A1 (en) 2020-11-05
WO2020223678A1 (en) 2020-11-05
US12479806B2 (en) 2025-11-25
MX2021013211A (es) 2022-03-11
SG11202111993SA (en) 2021-11-29
IL287673B1 (en) 2026-01-01
EP3962898A1 (en) 2022-03-09
MA55808A (fr) 2022-03-09
JP7630444B2 (ja) 2025-02-17
CN114040909A (zh) 2022-02-11
IL287673A (en) 2021-12-01
BR112021021706A2 (pt) 2022-04-19
KR20220004142A (ko) 2022-01-11
AU2020266170B2 (en) 2026-02-26
CN114040909B (zh) 2025-06-03

Similar Documents

Publication Publication Date Title
CR20210590A (es) Proceso para la preparación de inhibidores de xpo1 y productos intermedios para su uso en la preparación de inhibidores de xpo1
PE20220430A1 (es) PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA
MX2022011755A (es) Proceso, composiciones y formas cristalinas de compuestos de piridinona-piridinilo sustituidos.
AR120457A1 (es) Síntesis mejorada del compuesto inhibidor de g12c de kras
AR117814A1 (es) Compuestos moduladores de fxr (nr1h4)
UY39801A (es) Un proceso novedoso para la preparación de diamidas antranílicas
ECSP088368A (es) Derivados de 3-alquil-5-(4-alquil-5-oxo-tetrahidrofuran-2-il)-pirrolidin-2-ona como intermediarios en la síntesis de inhibidores de renina
BR112022012153A2 (pt) Processo para preparar um composto e composto
AR061310A1 (es) Procesos para preparar compuestos intermediarios utiles para la preparacion de cinacalcet
TW201502124A (zh) 製備苯并咪唑衍生物之方法
ECSP077167A (es) Nuevos compuestos heterociclicos
DOP2025000064A (es) Proceso para la preparación de un agente de contraste de gadolinio
CO2024010726A2 (es) Compuestos heterocíclicos y métodos de uso
ES2650247T3 (es) Procedimiento de preparación del bosentán
PE20081497A1 (es) Nuevo procedimiento para la preparacion de 4-4'-(1-metil-1,2-etandiil)-bis-(2,6-piperazindiona)
PE20110163A1 (es) Proceso para la preparacion de derivados de pirimidina sustituidos
CL2023003899A1 (es) Procesos para la preparación de derivados de (s)-2-(4-cloro-2-metoxifenil)-2-(3-metoxi-5-(metilsulfonil)fenil)amino)-1-(1h-indol-3-il)etenona.
AR071005A1 (es) Preparacion selectiva de pirimidinas sustituidas
EA021733B1 (ru) Ключевые промежуточные соединения для синтеза розувастатина или его фармацевтически приемлемых солей
EA200201122A1 (ru) Способ получения производного тетразола
CL2012000739A1 (es) Procedimientos de preparacion del acido 2-[(3,5-difluoro-3'-metoxi-1,1'-bifenil-4-il)amino]nicotinico; y uno de los compuestos intermedios considerados.
MX2024015016A (es) Proceso para la preparacion de derivados de eter, tioeter o amina secundaria en la presencia de un catalizador acido heterogeneo
ES2568927T3 (es) Proceso para fabricar derivados de adamantano con alto rendimiento
MX2012008152A (es) Proceso para preparar voriconazol utilizando nuevos intermediarios.
BRPI0516932A (pt) processo para a preparação de compostos de purina